Treatment Concepts for Wake-Up Stroke and Stroke with Unknown Time of Symptom Onset
Stroke 46:2707-2713, Thomalla, G. & Gerloff, C., 2015
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke
Stroke 46:2591-2598, Ganesalingam, J.,et al, 2015
Basilar Occlusion Syndromes: An Update
Neurohosp 5:142-150, Demel, S.L. & Broderick, J.P., 2015
Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion
JAMA Neurol 72:1148-1154, Schrag, M.,et al, 2015
IV Thrombolysis in Patients with Ischemic Stroke and Alcohol Abuse
Neurol 85:1592-1597, Gattringer, T.,et al, 2015
IV Thrombolysis in very severe and severe ischemic stroke
Neurol 85:2098-2106, Mazyam, M.V.,et al, 2015
Endovascular Therapy is Effective and Safe for Patients with Severe Ischemic Stroke
Stroke 46:3416-3422, Broderick, J.P.,et al, 2015
Endovascular vs Medical Management of Acute Ischemic Stroke
Neurol 85:1980-1990, Chen, C.J.,et al, 2015
Brush Sign on 3-T T2* - Weighted MRI as a Potential Predictor of Hemorrhagic Transformation After Tissue Plasminogen Activator Therapy
Stroke 45:274-276, Terasawa, Y.,et al, 2014
4.5-Hour Time Window for Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator is Established Firmly
Stroke 45:912-913,916, Schellinger, P.D. & Kohrmann, M., 2014
The 4.5-HourTime Window for Intravenous Thrombolysis with Intravenous Tissue-Type Plasminogen Activator is Not Firmly Established
Stroke 45:915-915,916, Wechsler, L.R., 2014
Preexisting Cerebral Microbleeds on Susceptibility-Weighted Magnetic Resonance Imaging and Post-Thrombolysis Bleeding Risk in 392 Patients
Stroke 45:1684-1688, Gratz, P.P.,et al, 2014
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Reperfusion Therapies for Wake-Up Stroke
Stroke 45:1869-1875, Buck, D.,et al, 2014
Safety of Thrombolysis in Patients with Acute Ischemic Stroke and Cerebral Cavernous Malformations
Stroke 45:1846-1848, Erdur, H.,et al, 2014
Unexplained Early Neurological Deterioration After Intravenous Thrombolysis
Stroke 45:2004-2009, Seners, P.,et al, 2014
Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
JAMA Neurol 81:1181-1185, Yaghi, S.,et al, 2014
Number of Cerebral Microbleeds and Risk of Intracerebral Hemorrhage after Intravenous Thrombolysis
Stroke 45:2900-2905, Dannenberg, S.,et al, 2014
Stroke and the Law
Stroke 45:3141-3146, Fisher, M. & Schneider, P., 2014
Safety of Thrombolysis in Stroke Mimics
Stroke 44:1080-1084, Zinkstok, S.M.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke
NEJM 368:914-923,952, Ciccone, A.,et al, 2013
Treatment of Patients with Suspected Ischemic Stroke of Undetermined Onset and Negative Head Computed Tomography Scan
Stroke 44:1494-1495, Adams, H., 2013
A Plain Computed Tomography Scan is Sufficient to Consider Thrombolysis in Patients with Unknown Time of Onset
Stroke 44:1492-1493, Alexandrov, A., 2013
Computed Tomography Angiography in Hyperacute Ischemic Stroke
Stroke 44:1480-1488, Mortimer, A.,et al, 2013
Negative Diffusion-Weighted Imaging After Intravenous Tissue-Type Plasminogen Activator is Rare and Unlikely to Indicate Averted Infarction
Stroke 44-1629-1634, Freeman, J.,et al, 2013
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013
Comparison of Final Infarct Volumes in Patients who Received Endovascular Therapy or Intravenous Thrombolysis for Acute Intracranial Large-Vessel Occlusions
JAMA Neurol 70:831-836, Rangaraju, S.,et al, 2013
Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013
New Appearance of Extraischemic Microbleeds on T2*-Weighted Magnetic Resonance Imaging 24 Hours After Tissue-Type Plasminogen Activator Administration
Stroke 44:2776-2781, Kimura, K.,et al, 2013
Thrombolysis for Ischemic Stroke Associated with Infective Endocarditis
Stroke 44:2917-2919, Asaithambi, G.,et al, 2013
Safety of Intravenous Thrombolysis for Ischemic Stroke in Patients Treated with Warfarin
Ann Neurol 74:266-274, Mazya, M.V.,et al, 2013
Serum Creatinine May Indicate Risk of Symptomatic Intracranial Hemorrhage after Intravenous Tissue Plasminogen Activator (IV tPA)
Medicine 92:317-323, Marsh, E.B.,et al, 2013
IV Thrombolysis and Renal Function
Neurol 81:1780-1788, Gensicke, H.,et al, 2013
Thrombolysis for Acute Ischemic Stroke in Patients with Cancer
Stroke 44:3573-3576, Murthy, S.B.,et al, 2013
Glycosylated Hemoglobin A1 Predicts Risk for Symptomatic Hemorrhage After Thrombolysis for Acute Stroke
Stroke 44:2134-2138, Rocco, A.,et al, 2013
The Safety of Intravenous Thrombolysis for Ischemic Stroke in Patients with Pre-Existing Cerebral Aneurysms
Stroke 43:412-416, Edwards,N.J.,et al, 2012
Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients with Stroke?
Stroke 43:878-880, Olson,M.D. and Rabinstein,A.A., 2012
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Safety of Thrombolysis in Patients Over the Age of 80
The Neuroogist 18:99-101, Willey,J.Z.,et al, 2012
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
NEJM 366:1099-1107, Parsons,M.,et al, 2012
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Acute Stroke Imaging: What is Sufficient for Triage to Endovascular Therapies?
AJNR 33:790-792, Lev, M.H., 2012
Factors Influencing In-Hospital Delay in Treatment with Intravenous Thrombolysis
Stroke 43:1578-1583, Mikulik, R.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
Early Administration of Aspirin in Patients Treated with Alteplase for Acute Ischaemic Stroke: A Randomised Controlled Trial
Lancet 380:731-737, Zinkstok, S.M.,et al, 2012
A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial
Stroke 43:2331-2335, Song, S.S.,et al, 2012